2021
Management of Refractory Ascites Due to Portal Hypertension: Current Status.
Madoff DC, Cornman-Homonoff J, Fortune BE, Gaba RC, Lipnik AJ, Yarmohammadi H, Ray CE. Management of Refractory Ascites Due to Portal Hypertension: Current Status. Radiology 2021, 298: 493-504. PMID: 33497318, DOI: 10.1148/radiol.2021201960.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRefractory ascitesPortal hypertensionTransjugular intrahepatic portosystemic shuntLarge-volume paracentesesCirrhotic portal hypertensionAvailable therapeutic optionsIntrahepatic portosystemic shuntStepwise management approachMost patientsMedical managementPoor prognosisPortosystemic shuntTherapeutic optionsTreatment optionsMultiple therapiesPatient outcomesAppropriate treatmentClinical experienceDrainage deviceSpecific patientAscitesHypertensionPatientsParacentesesPrognosis
2008
Yttrium-90 Microsphere Radioembolotherapy of Hepatic Metastatic Neuroendocrine Carcinomas after Hepatic Arterial Embolization
Murthy R, Kamat P, Nunez R, Madoff DC, Gupta S, Salem R, Yao JC. Yttrium-90 Microsphere Radioembolotherapy of Hepatic Metastatic Neuroendocrine Carcinomas after Hepatic Arterial Embolization. Journal Of Vascular And Interventional Radiology 2008, 19: 145-151. PMID: 18192482, DOI: 10.1016/j.jvir.2007.09.006.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiographyBrachytherapyCarcinoma, NeuroendocrineChemoembolization, TherapeuticFemaleFollow-Up StudiesHumansLiver NeoplasmsMaleMicrospheresMiddle AgedRetrospective StudiesTime FactorsTomography, Emission-Computed, Single-PhotonTomography, X-Ray ComputedTreatment OutcomeYttrium RadioisotopesConceptsNeuroendocrine hepatic metastasesHepatic metastasesEmbolization proceduresRadiation-induced liver diseaseYttrium-90 resin microspheresMetastatic neuroendocrine carcinomaCohort of patientsHepatic arterial embolizationTime of diagnosisReasonable therapeutic optionMedian survival timeHepatic artery radioembolizationHepatic progressionDisease stabilizationArterial embolizationPartial responseProgressive diseaseMedian ageLiver diseaseTherapeutic optionsStudy criteriaMicrosphere infusionNeuroendocrine carcinomaSurvival timeMicrosphere radioembolization